MiNK Therapeutics - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Samsung Galaxy M17 5G review: Is this budget Samsung phone worth buying at ₹15,498?

Samsung Galaxy M17 5G at ₹15,498: Hidden budget beast or just another overhyped Samsung phone?

Representative image of a Boeing C-17 Globemaster III during maintenance, illustrating Boeing’s $166.8 million landing gear spares contract modification and the growing strategic importance of military airlift sustainment.

Why Boeing’s $166.8 m C-17 spares win could matter more than it looks for BA stock

Why selective immune homeostasis is the bigger story behind CUE-401

Nida Khan in TCS Nashik case: Designation disputed, pregnancy cited for bail, police deploy four teams in ongoing manhunt

Read More

Pharma Industry News

MiNK Therapeutics surges over 700% after testicular cancer remission data fuels iNKT therapy optimism

MiNK Therapeutics stock explodes 730% after iNKT cell therapy shows full remission in metastatic cancer. Read what’s driving investor frenzy.

byPallavi Madhiraju

July 12, 2025

web analytics